Abstract
In the current COVID 19 pandemic, the only treatments are supportive as no definitive pharmacological intervention is available. The heterogeneity of the immune response in different patient groups is clear with less severe illness in children. Understanding these disparities is particularly important as severely affected patients with COVID19 cannot always be predicted before they experience a cytokine storm and multiorgan dysfunction. Over 100 years ago, the concept of individualised immunotherapy was introduced by Sir Almroth Wright and immortalised in GB Shaw’s play The Doctor’s Dilemma. Shaw’s play The Doctor’s Dilemma explores the issues of private medical practice, equality of health care delivery, rationing of scarce resources (intensive care) and high-risk therapies. The play also describes the dilemma of rationing of resources and selecting the correct patient for new experimental therapies. Immunological theories of the time are now reflected in current understanding of inflammatory responses in sepsis and immunomodulation during the COVID19 pandemic.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Shaw, G. B. The Doctor’s Dilemma. Preface. 1913 (Penguin Books, Baltimore, 1941).
Casadevall, A. & Pirofski, L. A. The convalescent sera option for containing COVID-19. J. Clin. Invest. 130, 1545–1548 (2020).
Dunn, P. M. Dr Leonard Colebrook, FRS (1883–1967) and the chemotherapeutic conquest of puerperal infection. Arch. Dis. Child. Fetal Neonatal Ed. 93, F246–F248 (2008).
Brown, K. Penicillin Man: Alexander Fleming and the Antibiotic Revolution (Sutton Publishing limited, 2004).
Colebrook, L. Almroth Wright. Provocative Doctor and Thinker (Heinemann Medical, London, 1954).
Dunnill, M. The Plato of Praed Street: The Life and Times of Almroth Wright (Royal Society of Medicine Press, London, 2000).
Molloy, E. J. et al. Neonatal sepsis: need for consensus definition, collaboration and core outcomes. Pediatr. Res. https://doi.org/10.1038/s41390-020-0850-5 (2020).
Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA https://doi.org/10.1001/jama.2020.4783 (2020).
Li, G. et al. Coronavirus infections and immune responses. J. Med. Virol. 92, 424–432 (2020).
Fu, Y., Cheng, Y. & Wu, Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol. Sin. https://doi.org/10.1007/s12250-020-00207-4 (2020).
Bone, R. C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24, 1125–1128 (1996).
Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138–150 (2003).
Ashare, A. et al. Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L633–L640 (2005).
Haveman, J. W. et al. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth. J. Med. 55, 132–41. (1999).
Osuchowski, M. F., Connett, J., Welch, K., Granger, J. & Remick, D. G. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit. Care Med. 37, 1567–1573 (2009).
Panacek, E. A. et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173–2182 (2004).
Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showprojen.aspx (2020).
Acknowledgements
This work was supported by Health Research Board, Ireland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Molloy, E.J. The Doctor’s Dilemma: lessons from GB Shaw in a modern pandemic COVID-19. Pediatr Res 89, 701–703 (2021). https://doi.org/10.1038/s41390-020-0927-1
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41390-020-0927-1
This article is cited by
-
Re-discovering white cell parameters in the diagnosis of sepsis and necrotising enterocolitis
Pediatric Research (2025)
-
Early immune modulation in cerebral palsy medical management of cerebral palsy series
Pediatric Research (2025)
-
Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management
Pediatric Research (2023)
-
Innate immune dysregulation in multisystem inflammatory syndrome in children (MIS-C)
Scientific Reports (2023)
-
Neonates and COVID-19: state of the art
Pediatric Research (2022)
